ES2666840T3 - Anticuerpos, kit y método in vitro para detectar beta-oligómeros amiloides - Google Patents

Anticuerpos, kit y método in vitro para detectar beta-oligómeros amiloides Download PDF

Info

Publication number
ES2666840T3
ES2666840T3 ES12737445.2T ES12737445T ES2666840T3 ES 2666840 T3 ES2666840 T3 ES 2666840T3 ES 12737445 T ES12737445 T ES 12737445T ES 2666840 T3 ES2666840 T3 ES 2666840T3
Authority
ES
Spain
Prior art keywords
antibody
ser
oligomers
antibodies
addl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12737445.2T
Other languages
English (en)
Spanish (es)
Inventor
William F. Goure
Renee C. GASPAR
Alexander Mccampbell
Mary J. Savage
Paul J. SHUGHRUE
Fubao Wang
Weirong Wang
Abigail L. WOLFE
Ningyan Zhang
Wei-Qin Zhao
Min Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Merck Sharp and Dohme LLC
Acumen Pharmaceuticals Inc
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Acumen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2011/043866 external-priority patent/WO2012009442A2/en
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC, Acumen Pharmaceuticals Inc filed Critical Merck Sharp and Dohme Ltd
Application granted granted Critical
Publication of ES2666840T3 publication Critical patent/ES2666840T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
ES12737445.2T 2011-07-13 2012-07-09 Anticuerpos, kit y método in vitro para detectar beta-oligómeros amiloides Active ES2666840T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161507332P 2011-07-13 2011-07-13
WOPCT/US2011/043866 2011-07-13
PCT/US2011/043866 WO2012009442A2 (en) 2010-07-14 2011-07-13 Anti-addl monoclonal antibody and uses thereof
US201161507332P 2011-07-13
PCT/US2012/045956 WO2013009703A2 (en) 2011-07-13 2012-07-09 Antibodies, kit and method for detecting amyloid beta oligomers

Publications (1)

Publication Number Publication Date
ES2666840T3 true ES2666840T3 (es) 2018-05-08

Family

ID=47506433

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12737445.2T Active ES2666840T3 (es) 2011-07-13 2012-07-09 Anticuerpos, kit y método in vitro para detectar beta-oligómeros amiloides

Country Status (13)

Country Link
US (2) US20130052670A1 (enExample)
EP (2) EP2732289B1 (enExample)
JP (1) JP2014521089A (enExample)
KR (1) KR20140072019A (enExample)
CN (1) CN103782171B (enExample)
AU (1) AU2012282825B2 (enExample)
BR (1) BR112014000671A2 (enExample)
CA (1) CA2840976A1 (enExample)
DK (1) DK2732289T3 (enExample)
ES (1) ES2666840T3 (enExample)
MX (1) MX2014000480A (enExample)
RU (1) RU2014105172A (enExample)
WO (2) WO2013009667A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3449926T (pt) 2009-06-17 2019-11-12 Cold Spring Harbor Laboratory Composições e métodos de modulação de excisões de smn2 em um sujeito
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
WO2014110291A1 (en) 2013-01-09 2014-07-17 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of smn2 splicing in a subject
ES2874704T3 (es) * 2013-11-20 2021-11-05 Univ Iowa Res Found Procedimiento para monitorizar la eficacia de un tratamiento de la enfermedad de Alzheimer con una isoforma de ApoE
MA39835A (fr) 2014-04-17 2017-02-22 Biogen Ma Inc Compositions et procédés de modulation de l'épissage du smn2 chez un patient
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
US10436802B2 (en) 2014-09-12 2019-10-08 Biogen Ma Inc. Methods for treating spinal muscular atrophy
MA41480A (fr) * 2014-10-17 2017-12-19 Glenmark Pharmaceuticals Sa Anticorps qui se lient au ccr6 et leurs utilisations
DK3341725T3 (da) * 2015-08-25 2021-09-06 Prothena Biosciences Ltd Fremgangsmåder til detektering af phosphoryleret alpha-synuklein
EP3415912B1 (en) 2016-02-08 2023-03-29 Sysmex Corporation Analyte detection method and reagent kit for detecting analyte
US11198867B2 (en) 2016-06-16 2021-12-14 Ionis Pharmaceuticals, Inc. Combinations for the modulation of SMN expression
CN114026109A (zh) * 2019-07-05 2022-02-08 株式会社岛津制作所 β淀粉样蛋白的单克隆抗体、和使用该抗体的β淀粉样蛋白相关肽的测定方法
CN120505310A (zh) 2020-02-28 2025-08-19 Ionis制药公司 用于调节smn2的化合物和方法
WO2022270901A1 (ko) * 2021-06-25 2022-12-29 장재원 동적 형광 또는 x-선의 표준편차와 자기상관을 활용한 조기 진단 시스템
WO2023034324A2 (en) * 2021-08-30 2023-03-09 The Brigham And Women’S Hospital, Inc. Methods and materials to treat neurodegenerative disease
WO2024026413A2 (en) * 2022-07-27 2024-02-01 Durin Technologies, Inc. Early detection and monitoring of neurodegenerative diseases using a multi-disease diagnostic platform
CN117589996A (zh) * 2022-08-09 2024-02-23 深圳智源生物医药有限公司 强毒性淀粉样蛋白寡聚体的诊断用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4665024A (en) 1984-10-01 1987-05-12 Becton, Dickinson And Company Fluorescent gram stain
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US6082205A (en) 1998-02-06 2000-07-04 Ohio State University System and device for determining particle characteristics
DE60043165D1 (de) 1999-08-04 2009-11-26 Univ Southern California Globularer Aufbau vom Amyloid-beta- protein und deren Verwendungen
CN1871517A (zh) * 2002-02-19 2006-11-29 免疫公司 快速有效分离循环癌细胞的方法和试剂
US7807157B2 (en) 2004-02-20 2010-10-05 Intellect Neurosciences Inc. Monoclonal antibodies and use thereof
CA2561532A1 (en) * 2004-04-02 2005-10-20 Merck & Co., Inc. Methods for detecting substances which bind to the amyloid precursor protein or beta amyloid fragments, and binding compounds
US7572640B2 (en) 2004-09-28 2009-08-11 Singulex, Inc. Method for highly sensitive detection of single protein molecules labeled with fluorescent moieties
NZ554725A (en) * 2004-10-25 2009-10-30 Merck & Co Inc Anti-ADDL antibodies and uses thereof
US7731962B2 (en) 2005-02-14 2010-06-08 Merck & Co., Inc. Anti-ADDL monoclonal antibody and use thereof
JP5289963B2 (ja) * 2005-10-21 2013-09-11 メルク・シャープ・アンド・ドーム・コーポレーション 抗ａｄｄｌモノクローナル抗体およびその使用
US20090181359A1 (en) * 2007-10-25 2009-07-16 Lou Sheng C Method of performing ultra-sensitive immunoassays
CN102666577A (zh) * 2009-11-24 2012-09-12 前体生物药物股份公司 诊断阿尔茨海默病或轻度认知损害的新的诊断方法
WO2011151076A2 (en) * 2010-06-04 2011-12-08 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
BR112013000796B1 (pt) * 2010-07-14 2021-08-31 Merck Sharp & Dohme Corp Anticorpo isolado ou um fragmento de ligação ao antígeno, composição farmacêutica, métodos para inibir a montagem de ligantes difusíveis derivados de ß-amiloide, para inibir a fosforilação de proteína tau em ser202/thr205, para identificar um suposto agente terapêutico, para detectar ligantes difusíveis derivados de ß-amiloide e para diagnosticar uma doença associada aos ligantes difusíveis derivados de ß-amiloide, e, kit para detectar ligantes difusíveis derivados de ß-amiloide

Also Published As

Publication number Publication date
AU2012282825A1 (en) 2014-01-16
EP2732289B1 (en) 2018-04-11
WO2013009667A1 (en) 2013-01-17
US20140120037A1 (en) 2014-05-01
CN103782171A (zh) 2014-05-07
EP2732286A4 (en) 2015-02-25
AU2012282825B2 (en) 2016-05-26
WO2013009703A3 (en) 2013-03-21
WO2013009703A2 (en) 2013-01-17
JP2014521089A (ja) 2014-08-25
KR20140072019A (ko) 2014-06-12
CN103782171B (zh) 2016-12-14
RU2014105172A (ru) 2015-08-20
BR112014000671A2 (pt) 2017-02-14
DK2732289T3 (en) 2018-05-22
EP2732286A1 (en) 2014-05-21
WO2013009703A8 (en) 2014-01-23
CA2840976A1 (en) 2013-01-17
EP2732289A2 (en) 2014-05-21
MX2014000480A (es) 2014-06-23
US20130052670A1 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
ES2666840T3 (es) Anticuerpos, kit y método in vitro para detectar beta-oligómeros amiloides
US10934348B2 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
ES2862427T3 (es) Anticuerpos específicos para tau hiperfosforilada y métodos de uso de los mismos
JP6168364B2 (ja) リン酸化タウ凝集体に対する抗体
US20100267816A1 (en) Human anti-amyloid beta peptide antibody and fragment of said antibody
Pascual et al. Immunological memory to hyperphosphorylated tau in asymptomatic individuals
AU2015213735A1 (en) Antibodies that bind to human Tau and assay for quantifying human Tau using the antibodies
KR20200130354A (ko) 신경퇴행을 검출하기 위한 분석
US9310383B2 (en) Antibodies, kit and method for detecting amyloid beta oligomers
TWI892069B (zh) 用於偵測Tau蛋白或其片段的方法與套組
US12509505B2 (en) Anti Tau SVQIVYKPV epitope single domain antibody
JP5605879B2 (ja) ｓＡＰＰβに対する抗体
RU2855123C1 (ru) Антитела против тау